Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2016 Dec;12(12):3043-3055.
doi: 10.1080/21645515.2016.1219809.

Immunogenicity of AS03-adjuvanted and non-adjuvanted trivalent inactivated influenza vaccines in elderly adults: A Phase 3, randomized trial and post-hoc correlate of protection analysis

Guillermo M Ruiz-Palacios  1 , Geert Leroux-Roels  2 , Jiri Beran  3 , Jeanne-Marie Devaster  4 , Meral Esen  5 , Odile Launay  6 , Janet E McElhaney  7 , Gerrit A van Essen  8 , Anne Benoit  9 , Carine Claeys  10 , Walthère Dewé  11 , Christelle Durand  12 , Xavier Duval  13 , Ann R Falsey  14 , Gregory Feldman  15 , Florence Galtier  16 , Pierre Gervais  17 , Shinn-Jang Hwang  18 , Shelly McNeil  19 , Jan Hendrik Richardus  20 , Andrew Trofa  21 , Lidia Oostvogels  22 ; Influence65 study group
Affiliations
Clinical Trial

Immunogenicity of AS03-adjuvanted and non-adjuvanted trivalent inactivated influenza vaccines in elderly adults: A Phase 3, randomized trial and post-hoc correlate of protection analysis

Guillermo M Ruiz-Palacios et al. Hum Vaccin Immunother. 2016 Dec.

Abstract

In this study we describe the immunogenicity results from a subset of older people (N = 5187) who participated in a Phase 3 randomized, observer-blinded trial of AS03-TIV versus TIV (Fluarix™) (ClinicalTrials.gov, NCT00753272). Participants received one dose of AS03-TIV or TIV in each study year and antibody titers against the vaccine strains were assessed using hemagglutination-inhibition (HI) assay at 21 d and 180 d post-vaccination in each vaccine group in the 2008/09 (Year 1) and 2009/10 (Year 2) influenza seasons. Manufacturing consistency of 3 lots of AS03-TIV for HI antibody responses in Year 1 was a co-primary objective. In a post-hoc analysis, a statistical regression model included 4830 subjects in whom immunogenicity and laboratory-confirmed attack rate data were available; the analysis was performed to assess HI antibody titers against A/H3N2 as a correlate of protection for laboratory-confirmed A/H3N2 influenza. AS03-TIV and TIV elicited strong HI antibody responses against each vaccine strain 21 d post-vaccination in both years. The manufacturing consistency of 3 lots of AS03-TIV was demonstrated. In both years and each vaccine group, HI antibody responses were lower for A/H1N1 than the other vaccine strains. Day 180 seroconversion rates (proportion with ≥4-fold increase in titer compared with pre-vaccination titer) in Year 1 in the AS03-TIV and TIV groups, respectively, were 87.7% and 74.1% for A/H3N2, 69.7% and 59.6% for influenza B, and 58.3% and 47.4% for A/H1N1. The post-hoc statistical model based on A/H3N2 attack rates and HI antibody titers estimated that a 4-fold increase in post-vaccination titers against A/H3N2 was associated with a 2-fold decrease in the odds of A/H3N2 infection.

Keywords: AS03; correlates of protection; immunogenicity; older; seasonal influenza; vaccine.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Participant flow chart. Note: AS03, tocopherol, oil-in-water emulsion-based Adjuvant System; CI, confidence intervals; TIV, inactivated trivalent influenza vaccine; Year 1, 2008/09; Year 2, 2009/10.
Figure 2.
Figure 2.
Day 21 hemagglutination-inhibition-based GMTs in the per-protocol immunogenicity cohort in Year 1 (A) and Year 2 (B). Note: AS03, tocopherol, oil-in-water emulsion-based Adjuvant System; CI, confidence intervals; TIV, inactivated trivalent influenza vaccine; GMT, geometric mean titer; N, number of subjects in the cohort with data available at time-point; Year 1, 2008/09; Year 2, 2009/10; Influenza A strains were A/Brisbane/59/2007 (H1N1 strain) and A/Uruguay/716/2007 (H3N2 strain); Influenza B strains were B/Brisbane/3/2007 (Victoria lineage) in Year 1 and B/Brisbane/60/2008 (Yamagata lineage) in Year 2.
Figure 3.
Figure 3.
Day 21 and 180 hemagglutination-inhibition-based GMTs in the per-protocol immunogenicity persistence cohorts in Year 1 (A) and Year 2 (B). Note: AS03, tocopherol, oil-in-water emulsion-based Adjuvant System; CI, confidence intervals; TIV, inactivated trivalent influenza vaccine; N, number of subjects in the cohort with data available at time-point; GMT, geometric mean titer; Year 1, 2008/09; Year 2, 2009/10; Influenza A strains were A/Brisbane/59/2007 (H1N1 strain) and A/Uruguay/716/2007 (H3N2 strain); Influenza B strains were B/Brisbane/3/2007 (Victoria lineage) in Year 1 and B/Brisbane/60/2008 (Yamagata lineage) in Year 2.
Figure 4.
Figure 4.
Day 21 and 180 hemagglutination-inhibition-based SCRs in the per-protocol immunogenicity persistence cohorts in Year 1 (A) and Year 2 (B). Note: AS03, tocopherol, oil-in-water emulsion-based Adjuvant System; CI, confidence intervals; TIV, inactivated trivalent influenza vaccine; N, number of subjects in the cohort with data available at time-point; Year 1, 2008/09; Year 2, 2009/10; Influenza A strains were A/Brisbane/59/2007 (H1N1 strain) and A/Uruguay/716/2007 (H3N2 strain); Influenza B strains were B/Brisbane/3/2007 (Victoria lineage) in Year 1 and B/Brisbane/60/2008 (Yamagata lineage) in Year 2; SCR, seroconversion rate defined as the proportion of seronegative subjects at baseline with post-vaccination titer of ≥1:40, or pre-vaccination titer of ≥1:10 and ≥4-fold increase post-vaccination.
Figure 5.
Figure 5.
Number of subjects in each titer category and number of A/H3N2 cases (A) and proportion of subjects in each titer category with PCR-confirmed A/H3N2 infection (B) in the immunogenicity subset.
Figure 6.
Figure 6.
A/H3N2 HI antibody titer and estimated risk of A/H3N2 influenza infection overall (A), in a low/moderate season (B) and in a high season (C) in the immunogenicity subset. Note: Points represent the observed proportions of cases and the dotted curve show 95% confidence interval; HI, hemagglutination-inhibition.
See this image and copyright information in PMC

References

    1. McElhaney JE. The unmet need in the elderly: designing new influenza vaccines for older adults. Vaccine 2005; 23(Suppl 1):S10-25 - PubMed
    1. McElhaney JE, Dutz JP. Better influenza vaccines for older people: what will it take? J Infect Dis 2008; 198:632-4; PMID:18652548; http://dx.doi.org/ 10.1086/590435 - DOI - PubMed
    1. Jefferson T, Rivetti D, Rivetti A, Rudin M, Di Pietrantonj C, Demicheli V. Efficacy and effectiveness of influenza vaccines in elderly people: a systematic review. Lancet (London, England) 2005; 366:1165-74; PMID:16198765; http://dx.doi.org/ 10.1016/S0140-6736(05)67339-4 - DOI - PubMed
    1. Arakane R, Annaka R, Takahama A, Ishida K, Yoshiike M, Nakayama T, Takeshita F. Superior immunogenicity profile of the new intradermal influenza vaccine compared to the standard subcutaneous vaccine in subjects 65 years and older: A randomized controlled phase III study. Vaccine 2015; 33:6650-8; PMID:26519549; http://dx.doi.org/ 10.1016/j.vaccine.2015.10.088 - DOI - PubMed
    1. DiazGranados CA, Dunning AJ, Jordanov E, Landolfi V, Denis M, Talbot HK. High-dose trivalent influenza vaccine compared to standard dose vaccine in elderly adults: safety, immunogenicity and relative efficacy during the 2009-2010 season. Vaccine 2013; 31:861-6; PMID:23261045; http://dx.doi.org/ 10.1016/j.vaccine.2012.12.013 - DOI - PubMed

Publication types

MeSH terms

Associated data